References
- Pegram MD Lipton A Hayes DF et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment . J. Clin. Oncol.16 ( 8 ), 2659 – 2671 ( 1998 ).
- Van Cutsem E Köhne CH Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer . N. Engl. J. Med.360 ( 14 ), 1408 – 1417 ( 2009 ).
- Aguiar PN Jr Santoro IL Tadokoro H et al. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis . Immunotherapy8 ( 4 ), 479 – 488 ( 2016 ).
- Cheng CJ Tietjen GT Saucier-Sawyer JK Saltzman WM . A holistic approach to targeting disease with polymeric nanoparticles . Nat. Rev. Drug Discov.14 ( 4 ), 239 – 247 ( 2015 ).
- Ryu JH Lee S Son S et al. Theranostic nanoparticles for future personalized medicine . J. Control. Release190 , 477 – 484 ( 2014 ).
- Ryu JH Lee A Chu JU et al. Early diagnosis of arthritis in mice with collagen-induced arthritis, using a fluorogenic matrix metalloproteinase 3-specific polymeric probe . Arthritis Rheum.63 ( 12 ), 3824 – 3832 ( 2011 ).
- Schmieder AH Winter PM Caruthers SD et al. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles . Magn. Reson. Med.53 ( 3 ), 621 – 627 ( 2005 ).
- de Jong M Breeman WA Kwekkeboom DJ Valkema R Krenning EP . Tumor imaging and therapy using radiolabeled somatostatin analogues . Acc. Chem. Res.42 ( 7 ), 873 – 880 ( 2009 ).
- Gener P Gouveia LP Sabat GR et al. Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells . Nanomedicine11 ( 8 ), 1883 – 1892 ( 2015 ).
- Kharazian B Hadipour NL Ejtehadi MR . Understanding the nanoparticle-protein corona complexes using computational and experimental methods . Int. J. Biochem. Cell Biol.75 , 162 – 174 ( 2016 ).
- Bertoli F Garry D Monopoli MP Salvati A Dawson KA . The intracellular destiny of the protein corona: a study on its cellular internalization and evolution . ACS Nano ( 2016 ) ( Epub ahead of print ).
- Sayari E Dinarvand M Amini M et al. MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery . Int. J. Pharm.473 ( 1–2 ), 304 – 315 ( 2014 ).
- Sánchez-Moreno P Buzón P Boulaiz H et al. Balancing the effect of corona on therapeutic efficacy and macrophage uptake of lipid nanocapsules . Biomaterials61 , 266 – 278 ( 2015 ).
- Safavi-Sohi R Maghari S Raoufi M et al. Bypassing protein corona issue on active targeting: zwitterionic coatings dictate specific interactions of targeting moieties and cell receptors . ACS Appl. Mater. Interfaces8 ( 35 ), 22808 – 22818 ( 2016 ).
- Untch M Jackisch C Schneeweiss A et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breastcancer (GeparSepto-GBG 69): a randomised, Phase III trial . Lancet Oncol.17 ( 3 ), 345 – 356 ( 2016 ).
- Goldstein D El-Maraghi RH Hammel P et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a Phase III trial . J. Natl Cancer Inst.107 ( 2 ), dju413 ( 2015 ).
- Tabernero J Shapiro GI LoRusso PM et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement . Cancer Discov.3 ( 4 ), 406 – 417 ( 2013 ).
- Yang Q Lai SK . Anti-PEG immunity: emergence, characteristics, and unaddressed questions . Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.7 ( 5 ), 655 – 677 ( 2015 ).
- Wilhelm S Tavares AJ Dai Q et al. Analysis of nanoparticle delivery to tumors . Nat. Rev. Mater.1 , 16014 ( 2016 ).